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Intermediate-Term Risk of Stroke Following Cardiac Procedures in a
Nationally Representative Data Set
Laura Stein, MD; Alison Thaler, MD; John W. Liang, MD; Stanley Tuhrim, MD; Amit S. Dhamoon, MD, PhD; Mandip S. Dhamoon, MD, DrPH
Background-—Studies on stroke risk following cardiac procedures addressed only perioperative and long-term risk following
limited higher-risk procedures, were poorly generalizable, and often failed to stratify by stroke type. We calculated stroke risk in the
intermediate risk period following cardiac procedures compared with common noncardiac surgeries and medical admissions.
Methods and Results-—The Nationwide Readmissions Database contains readmission data for 49% of US admissions in 2013. We
compared age-adjusted stroke readmission rates up to 90 days postdischarge. We used Cox regression to calculate hazard ratios,
up to 1 year, of stroke risk comparing transcatheter aortic valve replacement versus surgical aortic valve replacement and
coronary artery bypass graft versus percutaneous coronary intervention. Procedures and diagnoses were identiﬁed by International
Classiﬁcation of Disease, Ninth Revision, Clinical Modiﬁcation codes. After cardiac procedures, 90-day ischemic stroke
readmission rate was highest after transcatheter aortic valve replacement (2.05%); 90-day hemorrhagic stroke rate was highest
after left ventricular assist device placement (0.09%). The hazard ratio for ischemic stroke after transcatheter aortic valve
replacement, compared with surgical aortic valve replacement, in fully adjusted Cox models was 1.86 (95% conﬁdence interval,
1.12–3.08; P=0.016) and 6.17 (95% conﬁdence interval, 1.97–19.33; P=0.0018) for hemorrhagic stroke. There was no difference
between coronary artery bypass graft and percutaneous coronary intervention.
Conclusions-—We demonstrated elevated readmission rates for ischemic and hemorrhagic stroke in the intermediate 30-, 60-, and
90-day risk periods following common cardiac procedures. Furthermore, we found an elevated risk of stroke after transcatheter
aortic valve replacement compared with surgical aortic valve replacement up to 1 year. ( J Am Heart Assoc. 2017;6:e006900.
DOI: 10.1161/JAHA.117.006900.)
Key Words: cardiac surgery • epidemiology • stroke
C ardiac surgery has life-saving potential for many patients,but is also associated with signiﬁcant morbidity and
mortality, including the complication of stroke. Existing
literature on stroke risk following cardiac procedures focuses
on the perioperative and long-term risk periods following
cardiac surgery and known high-risk procedures, including left
ventricular assist device (LVAD) placement, aortic valve
replacement, coronary artery bypass graft (CABG), and
percutaneous coronary intervention (PCI).1–7 Most studies
involve single centers or device registries, with small sample
sizes and variable results.8–10 Also, most studies have not
stratiﬁed by stroke type or contextualized results by compar-
ing with other procedures and medical admissions. Further-
more, there are a paucity of data related to stroke risk in the
intermediate risk period after discharge from the procedure
and up to 1 year of follow-up. Recently, this risk period has
been highlighted by the Centers for Medicare & Medicaid
Services, with penalties for readmissions within 30 days.
There may also be implications for treatments to reduce
stroke risk that are targeted only to an intermediate risk
period.11
We used a nationally representative database to calculate
risk of stroke in the intermediate risk period following
common cardiac procedures. We hypothesized that there
was an elevated risk of ischemic and hemorrhagic stroke in
this period following cardiac procedures compared with
common noncardiac surgeries and medical admissions. We
also focused on 2 salient comparisons: (1) transcatheter
aortic valve replacement (TAVR) versus surgical aortic valve
replacement (SAVR) and (2) CABG versus PCI, procedures for
similar underlying conditions with different degrees of inva-
siveness. The overall goal was to provide nationally
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representative risk data that could help guide risk-beneﬁt
decisions and improve care in the vulnerable, but understud-
ied, intermediate risk period.
Methods
The Nationwide Readmissions Database is a national
database of readmissions for all payers and the uninsured
with data on more than 14 million US admissions during the
year 2013. It is 1 of 7 databases in the Healthcare Cost and
Utilization Project and is derived from State Inpatient
Databases from 21 states, comprising data from 49.1% of
all US hospitalizations, excluding rehabilitation and long-term
acute-care hospitalizations. The Nationwide Readmissions
Database allows analysis of readmissions with the use of an
anonymized, veriﬁed linkage identiﬁer for each individual. The
Mount Sinai Institutional Review Board reviewed and
approved this project, and all analyses comply with the
Healthcare Cost and Utilization Project data use agreement.
Because the data are made publicly available through the
Healthcare Cost and Utilization Project, the data, analytical
methods, and study materials will not be made available to
other researchers for purposes of reproducing the results or
replicating the procedure.
We used International Classiﬁcation of Disease, Ninth
Revision, Clinical Modiﬁcation (ICD-9-CM) codes to identify
index cardiac procedures, noncardiac procedures, and com-
mon medical admissions, as well as comorbidities. Cardiac
procedures included ablation, cardioversion, CABG, cardiac
catheterization, implantable cardioverter deﬁbrillator place-
ment, left atrial appendage (LAA) closure, LVAD placement,
PCI, permanent pacemaker placement, SAVR, and TAVR. For
index cardiac admissions, we excluded those with more than
1 concurrent cardiac procedure. Noncardiac surgeries
included appendectomy, cystectomy, cholecystectomy, hernia
surgery, hip surgery, knee surgery, nephrectomy, prostatec-
tomy, shoulder surgery, spine surgery, and thyroid surgery.
For noncardiac index admissions, we excluded those with
concurrent cardiac procedures. Medical admissions included
chronic obstructive pulmonary disease (COPD), congestive
heart failure (CHF), pneumonia, and urinary tract infection
(UTI) and were deﬁned by appropriate ICD-9-CM codes in the
primary diagnosis position. For medical admissions, we
excluded those with concurrent cardiac procedures. Comor-
bidities included atrial ﬁbrillation or atrial ﬂutter, carotid artery
disease, coagulation disorders, congestive heart failure,
coronary artery disease, diabetes mellitus, hypertension,
hypercholesterolemia, obesity, peripheral artery disease, renal
failure, smoking history, and stroke history. Characteristics of
the index hospitalization were deﬁned by Healthcare Cost and
Utilization Project and included hospital bed size (small,
medium, or large), teaching hospital status (metropolitan
nonteaching, metropolitan teaching, and nonmetropolitan
hospital), income quartile of patient’s ZIP code, and National
Center for Health Statistics urban-rural location classiﬁcation
(“central” counties of metro areas of ≥1 million population,
“fringe” counties of metro areas of ≥1 million population,
counties in metro areas of 250 000–999 999 population,
counties in metro areas of 50 000–249 999 population,
micropolitan counties [population 10 000–49 999], and not
metropolitan or micropolitan counties). The All Patient Reﬁned
Diagnosis Related Groups (APR-DRGs) are designated using
3M Health Information Systems software. APR-DRGs now
classify patients into 25 major diagnostic categories, and then
further subdivide patients into 4 severity of illness subclasses
in terms of degree of loss of function (minor, moderate, major,
or extreme) and 4 risk of mortality subclasses (minor,
moderate, major, or extreme). These 2 subclasses are
calculated separately and may be different from one another.
Analysis of the APR-DRG has demonstrated that mortality rate
correlates with increasing APR-DRG risk of mortality scores,4
and the APR-DRG has been adapted to the VA health
system.4,5
Primary outcomes were ischemic stroke and hemorrhagic
stroke. We used ICD-9-CM codes previously validated in the
literature to identify patients with ischemic and hemorrhagic
stroke. Ischemic stroke was identiﬁed by 1 of the following
ICD-9-CM codes: 433.x1, 434.x1, and 436; and hemorrhagic
stroke was identiﬁed by 1 of the following codes: 430 and
431.12–14 Ischemic and hemorrhagic stroke, as well as
medical and surgical index events, were deﬁned using only
the primary diagnosis. To ensure that the stroke was not
related to another cardiac procedure performed during the
stroke readmission and therefore misattributed to the index
Clinical Perspective
What Is New?
• Compared with noncardiac surgeries, cardiac surgeries are
associated with higher rates of ischemic and hemorrhagic
stroke.
• The highest rates of stroke were observed after tran-
scatheter aortic valve replacement.
• In adjusted models, there were no differences in stroke
rates comparing coronary artery bypass surgery and
percutaneous coronary intervention.
What Are the Clinical Implications?
• Individuals who undergo the high-risk surgeries identiﬁed
here should be closely followed for risk of stroke, and
further research is needed that recognizes these high rates
of stroke, in order to develop strategies to make cardiac
interventions even safer from the perspective of stroke risk.
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procedure, we excluded patients who underwent a cardiac
procedure during the stroke readmission.
Statistical Analysis
We calculated baseline characteristics of each group (index
admission for cardiac procedure, noncardiac surgery, and
medical admission). For medical comorbidities and charac-
teristics of the index hospitalization, we calculated means and
SDs for continuous variables and frequencies and percent-
ages for categorical variables.
We calculated readmission rates as the number of
readmissions attributed to ischemic and hemorrhagic stroke
within 30, 60, and 90 days of discharge from the index
hospitalization, and reported rates as a percentage. In order
to account for different age distributions within each group,
we age-standardized rates to the 2010 US population. For
ischemic stroke outcomes, we excluded index admissions
with an ischemic stroke diagnosis, and for hemorrhagic stroke
outcomes, we excluded index admissions with a hemorrhagic
stroke diagnosis, because the objective was to study patients
readmitted with these diagnoses. To calculate 30-day read-
mission rates, we excluded index hospitalizations in Decem-
ber; to calculate 60-day rates, we excluded index
hospitalizations in November and December; and to calculate
90-day rates, we excluded index hospitalizations in October,
November, and December. We compared rates of ischemic
and hemorrhagic stroke after cardiac procedures with rates
following common noncardiac surgeries and medical admis-
sions.
Additionally, we performed 2-way comparisons of CABG
versus PCI and TAVR versus SAVR. For this analysis, we used
all available follow-up data and measured time from discharge
from the index hospitalization to admission for stroke.
Because only the month of admission, and not the exact
date, is available in the Nationwide Readmissions Database,
for those without the event of interest, we calculated the
maximum observed follow-up period as the number of days
from the midpoint of the month of index admission to
December 31, 2013. We assumed full capturing of mortality
and no loss to follow-up because all outcomes studied were
highly likely to result in hospitalization. For each comparison,
we created Kaplan–Meier curves of the cumulative risk of
ischemic and hemorrhagic stroke, stratiﬁed by index admis-
sion type. We performed Cox regression, reporting hazard
ratio and 95% conﬁdence intervals separately for the
outcomes of ischemic and hemorrhagic stroke. We ran an
unadjusted model, and then adjusted for risk of mortality,
based on the subclass assigned by 3M’s APR-DRG software,
based on likelihood of dying, with 1=minor, 2=moderate,
3=major, and 4=extreme. In a separate model, we adjusted
for severity of illness, based on the subclass assigned by 3M’s
APR-DRG software and classiﬁed similarly as the APR-DRG
risk of mortality. In another model, we adjusted for vascular
risk factors during the index admission, including age, atrial
ﬁbrillation or atrial ﬂutter, carotid artery disease, coagulation
disorders, congestive heart failure, coronary artery disease,
diabetes mellitus, hypertension, hypercholesterolemia, obe-
sity, peripheral artery disease, renal failure, smoking history,
and stroke history. The fully adjusted model was adjusted for
vascular risk factors, hospital bed size, teaching hospital
status, income quartile of patient’s ZIP code, and National
Center for Health Statistics urban-rural location classiﬁcation,
all measured at the time of index admission. The proportional
hazards assumption was not violated in these models.
Analyses were performed in SAS (version 9.4; SAS Institute
Inc, Cary, NC) and R (version 3.3.1; R Foundation for
Statistical Software, Vienna, Austria).
Results
Table 1 lists baseline characteristics of the study population
at the time of index event. There were 653 216 patients in the
cardiac procedure group, 1 198 209 in the noncardiac
surgery group, and 968 224 in the medical group. Noncardiac
surgery patients were younger, had fewer vascular risk
factors, and had lower estimated risk of mortality and illness
severity than the cardiac procedure and medical groups.
Among cardiac procedure patients, males outnumbered
females, and vascular risk factors were more common than
in the other groups. The most common cardiac procedures
were cardiac catheterization (191 400 for the ischemic stroke
analysis and 193 963 for hemorrhagic stroke) and permanent
pacemaker placement (61 841 for the ischemic stroke
analysis and 63 071 for hemorrhagic stroke).
Following cardiac procedures, noncardiac surgeries, and
medical admissions, readmission rates for ischemic and
hemorrhagic stroke increased from the 30-, 60-, to 90-day
periods following all index events, suggesting a progressive,
and not stepwise, risk in the intermediate follow-up period. In
the cardiac surgery group, readmission rate for ischemic
stroke was highest after TAVR and lowest after LAA closure
(Figure 1A). Notably, aside from LAA closure and ablation, the
ischemic stroke readmission rate following cardiac proce-
dures was still higher than the highest-risk noncardiac surgery
(Figure 2). The ischemic stroke readmission rates following
SAVR, cardiac catheterization, LVAD, and TAVR were all higher
than rates following admission for UTI, pneumonia (PNA), and
COPD (Figure 2). Hemorrhagic stroke readmission rates were
highest after LVAD and lowest following implantable car-
dioverter deﬁbrillator placement (Figure 1B).
Among the noncardiac surgery group, ischemic stroke
readmission rates were highest following cystectomy and
lowest after knee surgery (Figure 2). Hemorrhagic stroke
DOI: 10.1161/JAHA.117.006900 Journal of the American Heart Association 3





















Table 1. Baseline Characteristics of Study Population at Index Event





No. of participants 653 216 1 198 209 968 224
Age, y, mean (SD) 66.1 (13.3) 60.8 (15.9) 70.0 (16.6)
Male, N (%) 402 150 (61.6) 527 898 (44.1) 424 514 (43.8)
Median income for ZIP code, N (%)
$0 to 25 000 178 328 (27.8) 261 134 (22.2) 294 881 (31.0)
$25 001 to 30 000 170 203 (26.5) 304 869 (25.9) 261 197 (27.4)
$30 001 to 35 000 156 100 (24.3) 314 240 (26.7) 222 633 (23.4)
$35 001+ 137 297 (21.4) 297 954 (25.3) 173 919 (18.3)
APRDRG mortality risk, N (%)
Minor likelihood 245 606 (37.6) 913 019 (76.2) 242 980 (25.1)
Moderate likelihood 215 246 (33.0) 196 344 (16.4) 370 228 (38.2)
Major likelihood 140 659 (21.5) 68 802 (5.7) 298 987 (30.9)
Extreme likelihood 51 682 (7.9) 20 017 (1.7) 55 970 (5.8)
APRDRG illness severity subclass, N (%)
No or minor loss of function 169 030 (25.9) 556 375 (46.4) 110 129 (11.4)
Moderate loss of function 259 498 (39.7) 488 636 (40.8) 427 588 (44.2)
Major loss of function 170 850 (26.2) 125 544 (10.5) 375 699 (38.8)
Extreme loss of function 53 815 (8.2) 27 627 (2.3) 54 749 (5.7)
Atrial fibrillation or atrial flutter, N (%) 194 184 (29.7) 78 342 (6.5) 228 772 (23.6)
Carotid artery disease, N (%) 17 292 (2.7) 6370 (0.5) 11 527 (1.2)
Coagulation disorder, N (%) 45 482 (7.0) 33 738 (2.8) 55 969 (5.8)
Congestive heart failure, N (%) 196 101 (30.0) 42 948 (3.6) 406 681 (42)
Coronary artery disease, N (%) 469 046 (71.8) 143 922 (12.0) 322 361 (33.3)
Diabetes mellitus, N (%) 231 554 (35.5) 224 071 (18.7) 329 649 (34.1)
Hypertension, N (%) 383 991 (58.8) 587 146 (49.0) 451 320 (46.6)
Hyperlipidemia, N (%) 406 639 (62.3) 395 659 (33.0) 367 786 (38.0)
Obesity, N (%) 114 316 (17.5) 201 452 (16.8) 134 280 (13.9)
Peripheral artery disease, N (%) 57 954 (8.9) 32 048 (2.7) 70 382 (7.3)
Renal failure, N (%) 80 931 (12.4) 46 997 (3.9) 142 773 (14.8)
Smoking history, N (%) 242 604 (37.1) 287 774 (24.0) 328 676 (34.0)
Stroke history, N (%) 37 277 (5.7) 20 775 (1.7) 58 311 (6.0)
Primary expected payer, N (%)
Medicare 383 730 (58.8) 564 046 (47.1) 692 216 (71.6)
Medicaid 46 695 (7.2) 83 759 (7.0) 87 374 (9.0)
Private insurance 165 373 (25.4) 442 526 (37.0) 122 237 (12.6)
Self-pay 29 633 (4.5) 37 442 (3.1) 34 680 (3.6)
No charge 4608 (0.7) 5529 (0.5) 4734 (0.5)
Other 22 385 (3.4) 63 755 (5.3) 2587 (2.7)
Length of stay, day, mean (SD) 5.5 (7.4) 4.2 (5.8) 4.8 (5.6)
APRDRG indicates All Patient Reﬁned Diagnosis Related Group.
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readmission rates were highest following thyroid surgery and
lowest after appendectomy (Figure 2). After medical index
admissions, ischemic stroke readmission rates were highest
for CHF, comparable with that observed following LVAD, and
lowest for COPD, comparable with rates following ablation
(Figure 2). Hemorrhagic stroke readmission rates were also
highest following admission for CHF and lowest for COPD.
Hemorrhagic stroke readmission rates following UTI and
pneumonia were comparable to those following CABG,
cardioversion, and PCI (Figure 2).
In direct comparison of CABG versus PCI, there was no
statistically signiﬁcant difference in hazards of ischemic or
hemorrhagic stroke in both unadjusted and adjusted models
(Table 2). There was, however, a consistently elevated
cumulative risk of ischemic and hemorrhagic stroke after TAVR
comparedwith SAVR (Figure 3A and 3B) that was also observed
in unadjusted and adjusted Cox models (Table 2). The hazard
ratio for ischemic stroke after TAVR, compared with SAVR, in
fully adjusted Cox models, was 1.86 (95% conﬁdence interval,
1.12–3.08; P=0.016) and 6.17 (95% conﬁdence interval, 1.97–
19.33; P=0.0018) for hemorrhagic stroke.
Discussion
This study demonstrates elevated readmission rates for
ischemic and hemorrhagic stroke in the intermediate 30-,
60-, and 90-day risk periods following common cardiac
procedures relative to noncardiac procedures and common
Figure 1. Readmission rates for ischemic (A) and hemorrhagic (B) stroke after cardiac procedures. CABG
indicates coronary artery bypass graft; Cath, cardiac catheterization; ICD, implantable cardioverter
deﬁbrillator placement; LAA closure, left atrial appendage closure; LVAD, left ventricular assist device
placement; PCI, percutaneous coronary intervention; PPM, permanent pacemaker placement; Surgical AVR,
surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.
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medical admissions. Ischemic stroke risk was highest follow-
ing TAVR and LVAD, and hemorrhagic stroke risk was highest
following LVAD, SAVR, and LAA closure. Aside from LAA
closure, all cardiac procedures were associated with a higher
readmission risk for stroke than noncardiac procedures. The
ischemic stroke readmission rates following SAVR, cardiac
catheterization, permanent pacemaker placement, and
implantable cardioverter deﬁbrillator placement were all
higher than rates following admission with UTI, pneumonia,
and COPD. Ischemic stroke readmission rates following LVAD
and TAVR were higher than rates following admission with
CHF. These results suggest that the cardiac procedures and
postoperative management confer additional vulnerability to
patients who have many concurrent vascular risk factors in
the intermediate risk period.
In a Japanese nation-wide benchmarking project examining
30-day postoperative complications for CABG, valve opera-
tions, and thoracic aortic operations, risk of stroke was
highest following thoracic aortic operation (6.8%), valve
operation (1.8%), and CABG (1.5%).1 Different risk periods
and subtype of stroke were not examined. Also, this study did
not examine rates after a number of important cardiac
procedures and did not compare rates with those after
medical admissions and noncardiac surgeries. Finally, results
may not be generalizable to the US population, whereas the
current study includes data from half of all US hospitalizations
in 2013.
With the advent of minimally invasive transcatheter
approaches, researchers have paid great attention to out-
comes following aortic valve replacement and attempted to
risk stratify candidates for replacement based on symptom
severity and medical comorbidities. Reported rates of stroke
after aortic valve replacement vary dramatically, are registry
based, and likely do not take into account an even higher
incidence of silent stroke.15 The American College of
Cardiology recently published an expert consensus decision
pathway for TAVR in adults with aortic stenosis, acknowledg-
ing that although TAVR is used for higher-risk patients, it will
increasingly be offered to lower-risk patients.16 We directly
compared TAVR and SAVR and found an almost 90%
increased risk of ischemic stroke with TAVR compared with
SAVR, and more than 6-fold increased risk of hemorrhagic
stroke. The Nordic Aortic Valve Intervention Trial showed no
difference in stroke or transient ischemic attack at 30 days or
1 year in patients undergoing TAVR versus SAVR, regardless
of predicted risk of death following surgery.17 Similarly, the
PARTNER (Placement of Aortic Transcatheter Valves) 2 Trial
showed no difference in stroke risk in intermediate-risk
Figure 2. Ninety-day age-adjusted readmission rates for ischemic and hemorrhagic stroke by index event.
CABG indicates coronary artery bypass graft; Cath, cardiac catheterization; CHF, congestive heart failure;
COPD, chronic obstructive pulmonary disease; ICD, implantable cardioverter deﬁbrillator placement; LAA
closure, left atrial appendage closure; LVAD, left ventricular assist device placement; PCI, percutaneous
coronary intervention; PNA, pneumonia; PPM, permanent pacemaker placement; Surgical AVR, surgical
aortic valve replacement; TAVR, transcatheter aortic valve replacement; UTI, urinary tract infection.
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patients at 30 days and 1 year.5,18 The similar risk following
TAVR and SAVR in the PARTNER trials could be attributed to
close follow-up these patients received as study participants.
Our results may reﬂect the real-world reality for the majority
of patients who are not followed closely in a clinical trial, and
highlight a need for closer follow-up in the vulnerable
intermediate risk period. Our results may also reﬂect the fact
that more high-risk patients are offered TAVR than SAVR at
present, but the elevated stroke risk following TAVR persisted
even after adjustment for risk factors and estimates of
mortality and illness severity.
In high-risk patients, Adams et al showed comparable
stroke risk at 30 days (4.9% in TAVR and 6.2% in SAVR;
P=0.46) and 1 year (8.8% and 12.6%; P=0.10). Also, in high-
risk patients in The CoreValue US High-Risk Pivotal Trial,
stroke risk following TAVR at 30 days, 1 year, and 2 years
was 4.9%, 8.7%, and 10.9%, respectively, and 6.2%, 12.5%, and
16.6%, respectively, for SAVR.4 This study distinguished
between hemorrhagic and ischemic stroke and found higher
overall rates of ischemic than hemorrhagic stroke following
TAVR and SAVR.
We, too, found higher rates of ischemic stroke than
hemorrhagic stroke following TAVR and SAVR. However, our
study accords more with the results of Smith et al, who found
a higher stroke incidence in the high-risk transcatheter group
with major stroke 30-day rates of 3.8% in the transcatheter
group and 2.1% in the surgical group (P=0.20) and 5.1% and
2.4%, respectively, at 1 year (P=0.07).7 There was, however,
no distinction between stroke subtypes and no examination of
the intermediate risk period. It is possible that some of our
difference is attributable to an inability to stratify by surgical
risk and a larger sample size. In another study, there was an
early stroke rate (2–30 days) of 3% and a higher late stroke
rate in the 31- to 730-day late period.3 While these risk
periods do not accord with our 30-, 60-, and 90-day
intermediate risk periods, they do suggest an incremental
increase in risk of stroke with time following TAVR. In another
study, 17.9% with TAVR were readmitted within 30 days, and
of those, 3.6% were readmitted with stroke or transient
ischemic attack.19 However, this study did not examine the
intermediate risk period beyond 30 days, compare readmis-
sion rates with other procedures or medical admissions, or
distinguish between ischemic and hemorrhagic stroke.
LVAD is known to be associated with a high risk of stroke.
Most past studies compare outcomes with different devices
within single centers.8–10 Using administrative claims data
Table 2. Unadjusted and Adjusted Cox Regression Models Testing 2-Way Comparisons for Risk of Ischemic and Hemorrhagic
Stroke
Ischemic Stroke Hemorrhagic Stroke
Hazard Ratio 95% CI P Value Hazard Ratio 95% CI P Value
Coronary artery bypass graft vs percutaneous coronary intervention (reference)
Unadjusted model 0.89 0.70 to 1.13 0.34 1.02 0.14 to 7.27 0.98
Adjusted for risk of mortality* 0.80 0.63 to 1.03 0.08 1.20 0.60 to 2.41 0.6
Adjusted for severity of illness† 0.74 0.58 to 0.95 0.017 1.21 0.59 to 2.46 0.6
Adjusting for vascular risk factors‡ 0.83 0.65 to 1.07 0.14 1.24 0.61 to 2.55 0.55
Adjusting for additional vascular risk factors§ 0.80 0.62 to 1.04 0.10 1.12 0.52 to 2.38 0.78
Fully adjustedk 0.80 0.62 to 1.05 0.11 1.09 0.51 to 2.34 0.8
Transcatheter aortic valve replacement vs surgical aortic valve replacement (reference)
Unadjusted model 2.28 1.52 to 3.41 <0.0001 6.53 2.67 to 15.97 <0.0001
Adjusted for risk of mortality* 2.13 1.40 to 3.22 0.0004 5.38 2.20 to 13.20 0.0002
Adjusted for severity of illness† 2.34 1.40 to 3.91 0.001 3.03 0.98 to 9.30 0.053
Adjusted for vascular risk factors‡ 1.85 1.15 to 2.96 0.01 4.53 1.53 to 13.45 0.006
Adjusting for additional vascular risk factors§ 1.75 1.07 to 2.86 0.026 4.59 1.53 to 13.74 0.007
Fully adjustedk 1.86 1.12 to 3.08 0.016 6.17 1.97 to 19.33 0.0018
CI indicates conﬁdence interval.
*Adjusted for 3M’s All Patient Reﬁned Diagnosis Related Group (APR-DRG) Risk of Mortality, classiﬁed as: 1=minor, 2=moderate, 3=major, 4=extreme.
†Adjusted for 3M’s All Patient Reﬁned Diagnosis Related Group (APR-DRG) Severity of Illness Subclass, classiﬁed as 1=minor, 2=moderate, 3=major, 4=extreme.
‡Adjusted for age, atrial ﬁbrillation or atrial ﬂutter, diabetes mellitus, hypertension, hypercholesterolemia, and smoking history.
§Adjusted for age, atrial ﬁbrillation or atrial ﬂutter, diabetes mellitus, hypertension, hypercholesterolemia, smoking history, coronary artery disease, cerebrovascular disease, peripheral
arterial disease, coagulation disorders, carotid artery disease, and obesity.
kAdjusted for all vascular risk factors as well as: hospital bed size, teaching hospital status, income quartile of patient’s ZIP code, and National Center for Health Statistics urban-rural
location classiﬁcation.
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from New York, California, and Florida, there was an 8.7%
annual risk of stroke following LVAD (5.5% ischemic, 3.1%
hemorrhagic).20 This annual incidence of stroke was similar in
another single-center study.9 While intermediate risk (up to
90 days) and annual risk are not directly comparable, the
current study also suggests that in the intermediate risk
period, patients were readmitted more commonly with
ischemic than hemorrhagic stroke after LVAD.
In previous studies of PCI and CABG, subsequent stroke
risk was found to be low. A retrospective cohort study in
California demonstrated 1-year stroke rates of 1.4% to 1.7%
for CABG, 1.2% to 1.6% for PCI performed in patients with
acute coronary syndrome, and 1% to 1.2% for PCI performed
in patients without acute coronary syndrome.6 In a retro-
spective cohort study in Europe comparing 30-day and 5-year
outcomes after PCI and CABG in patients aged ≤50 years, 30-
day stroke rate was 0% in the PCI group (n=1617) and 0.7%
after CABG (n=592). After 1 year, 99.6% were stroke free
after PCI and 99.3% after CABG.2 The current study compares
the risk following PCI and CABG to the risk following common
medical diagnoses, with a risk of readmission similar to that
following admission for UTI and pneumonia and lower than
CHF. We also directly compared stroke risk after CABG and
PCI, and found an unadjusted increased risk of ischemic
stroke after CABG that reversed after adjustment for
estimated risk of mortality and illness severity. However,
after full adjustment, hazards were similar for ischemic and
hemorrhagic stroke.
Most literature focuses on the perioperative and long-term
risk periods following cardiac surgery, whereas the current
study uniquely examines the intermediate risk period. This
risk period has been highlighted by the Centers for Medicare
& Medicaid Services, which has instituted signiﬁcant penalties
for readmissions within 30 days. There may also be implica-
tions for targeted treatments that apply only during the
intermediate period of risk. For example, a recent study
examining randomized trials of aspirin after transient ischemic
attack or ischemic stroke suggested that the intermediate risk
period (6–12 weeks) is most important in secondary preven-
tion.11 We suggest that there may be similar opportunities to
target patients in the intermediate postoperative period after
cardiac surgery. Further study could identify postoperative
interventions and monitoring that could lower the risk of
ischemic and hemorrhagic stroke following many common
cardiac procedures.
There are several limitations to this study. First, there may
be misclassiﬁcation of variables based on ICD-9CM codes,
and comorbidities may be incomplete. We could not adjust for
stroke severity, preprocedural risk, or medications. Second,
we could not fully observe out-of-hospital mortality. There are
several strengths of this study. We used data from a large,
nationally representative, and contemporary data set. Patients
were not selected by enrollment in a device registry or from a
single center. Additionally, it is imperative to distinguish
between ischemic and hemorrhagic stroke outcomes because
the management and risk-factor proﬁles differ for each. The
current study is unique because it highlights the intermediate
risk period, which has been understudied to date. Rather than
focusing on 1 or 2 cardiac procedures, we examined several
common cardiac procedures and noncardiac procedures, and
we contextualized rates to those following common medical
admissions.
In summary, we demonstrated elevated readmission rates
for ischemic and hemorrhagic stroke in the intermediate 30-,
60-, and 90-day risk periods following common cardiac
procedures. Furthermore, our data suggest an elevated risk of
stroke after TAVR compared with SAVR and similar risks
following CABG and PCI. Further study is required to better
understand mechanisms of increased intermediate risk for
these vulnerable patients that may allow the development of
targeted interventions during this risk period. Additionally,
patients might beneﬁt from the development of a risk index
calculator for stroke risk following cardiac and noncardiac
surgeries, similar to the Revised Cardiac Risk Index used to
A
B
Figure 3. A, Cumulative risk of ischemic stroke following
transcatheter aortic valve replacement vs surgical aortic
valve replacement. B, Cumulative risk of hemorrhagic stroke
following transcatheter aortic valve replacement vs surgical
aortic valve replacement. SAVR indicates surgical aortic valve
replacement; TAVR, transcatheter aortic valve replacement.
DOI: 10.1161/JAHA.117.006900 Journal of the American Heart Association 8





















calculate the risk of cardiac complications following noncar-
diac surgery.
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